32. Primary Biliary Cirrhosis

  1. John WD McDonald Professor of Medicine3,
  2. Andrew K Burroughs Professor of Hepatology Consultant Physician/Hepatologist4,
  3. Brian G Feagan Professor of Medicine3 and
  4. M Brian Fennerty Professor of Medicine5
  1. Gideon M Hirschfield1,2 and
  2. E Jenny Heathcote1,2

Published Online: 22 JUL 2010

DOI: 10.1002/9781444314403.ch32

Evidence-Based Gastroenterology and Hepatology, Third Edition

Evidence-Based Gastroenterology and Hepatology, Third Edition

How to Cite

Hirschfield, G. M. and Heathcote, E. J. (2010) Primary Biliary Cirrhosis, in Evidence-Based Gastroenterology and Hepatology, Third Edition (eds J. W. McDonald, A. K. Burroughs, B. G. Feagan and M. B. Fennerty), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444314403.ch32

Editor Information

  1. 3

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

  2. 4

    The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, and University College London, London, UK

  3. 5

    Oregon Health and Science University, Division of Gastroenterology and Hepatology, Portland, Oregon, USA

Author Information

  1. 1

    Francis Family Liver Centre, Toronto Western Hospital, University Health Network, Toronto, Canada

  2. 2

    Department of Medicine, University of Toronto, Toronto, Canada

Publication History

  1. Published Online: 22 JUL 2010
  2. Published Print: 10 SEP 2010

ISBN Information

Print ISBN: 9781405181938

Online ISBN: 9781444314403

SEARCH

Keywords:

  • Therapeutic trial design: assessment of credibility;
  • Randomized controlled trials of treatment for primary biliary cirrhosis;
  • The future for therapy in primary biliary cirrhosis;
  • Primary biliary cirrhosis (PBC);
  • more specific assays for AMA using ELISA technology;
  • anti-mitochondrial antibodies (AMA);
  • alkaline phosphatase (ALP);
  • ursodeoxycholic acid (UDCA);
  • Surrogate markers of outcome;
  • Reduction of cholestasis: ursodeoxycholic acid

Summary

This chapter contains sections titled:

  • Introduction

  • Diagnosis

  • Natural history

  • Surrogate markers of outcome

  • Therapeutic trial design: assessment of credibility

  • Randomized controlled trials of treatment for primary biliary cirrhosis

  • The future for therapy in primary biliary cirrhosis

  • References